Episode Summary
Executive Summary: The episode opens with a founder-advice segment on why monthly investor updates drive trust, follow-on capital, and operational discipline, then shifts to a deep interview with Ginkgo Bioworks CEO Jason Kelly on synthetic biology as programmable life. Kelly explains how DNA is like code, how Ginkgo acts as a "lab cloud" for biology, and why biosecurity, ethics, and trust will shape the field as gene editing, GMOs, and even de-extinction move forward.
Main Topics: Why monthly investor updates matter: The host argues founders should send concise monthly updates to build credibility, align teams, surface problems early, and keep investors engaged for future rounds. Synthetic biology as software for life: Kelly frames biology as digital code written in DNA, comparing Ginkgo’s platform to AWS: a scalable infrastructure that helps customers program cells to produce desired outputs. Automation and the scale-up of bioengineering: The discussion covers how robotics, standardized lab workflows, and high-throughput experimentation have dramatically increased speed and lowered cost in biological design and debugging. Biosecurity, regulation, and dual-use risk: They explore COVID-19, the threat of bad actors, and the need for biosecurity systems comparable to cybersecurity and fraud detection to accompany more powerful biology tools. Ethics of gene editing, GMOs, and human modification: The conversation distinguishes between widely accepted non-human applications and much more sensitive human germline changes, emphasizing trust, transparency, and public consent. Future applications: food, materials, and de-extinction: Kelly discusses using engineered biology for animal-free products, fertilizers, therapeutics, and potentially mammoths or bird-based dinosaur analogs, while noting practical and ethical limits. Ginkgo’s business model and public-market strategy: Ginkgo sells programming capability and captures value via royalties/equity, and it went public via SPAC to access capital and broaden public participation in the sector.
Key Arguments: Monthly investor updates are not just communication; they create operating discipline, surface issues early, and increase the odds of follow-on funding. Short updates with concrete metrics and charts are better than long narratives because investors respond to real progress, not hype. Synthetic biology works because DNA is digital code; cells are programmable, but unlike computers they remain noisy and require iterative debugging. Ginkgo’s role is to industrialize biological engineering by providing infrastructure, automation, and expertise so customers do not need to build expensive labs. Automation has made bioengineering dramatically faster and cheaper, enabling millions of designs and reducing the cost per lab operation. Biosecurity should evolve alongside biotech, because biology is more accessible than nuclear materials and can be misused without physical choke points. Non-human applications of biotech will scale faster than human enhancement because people will be conservative about changing their children’s DNA. Public trust, not just scientific safety, is the central issue for GMOs and other biotech products; transparency beats paternalistic messaging. Biology is likely to transform not just medicine but also food, materials, chemicals, and manufacturing because cells move atoms, not just information.
Data Points: Ginkgo valuation/business scale: $15 billion - Host introduces Ginkgo BioWorks as a company built into a roughly $15B business around the synthetic biology platform model. Monthly update cadence: Every month - Host argues founders should send investor updates on a monthly basis to maintain engagement and credibility. Failure signal threshold: 2-3 missed updates - Host says two or three missed investor updates is when investors start to worry and think the company may be failing. Lab output improvement: Tripling output yearly for 5 years - Kelly says Ginkgo has roughly tripled the facility’s output each year over five years through automation. Lab operation cost reduction: Halving annually - Kelly says the cost per lab operation has been cut by about 50% each year. Genome sequencing cost reduction: 1 million-fold - Kelly states the cost to sequence a human genome fell from about $100 million to about $100, a million-fold drop in 21 years. First human genome cost: About $100 million - Reference point for the original human genome sequencing effort. Current human genome cost: About $100 - Kelly cites Illumina and BGI pricing for sequencing a human genome today. Human genome size: 3-4 billion letters - Kelly references the approximate size of the human genome as a code base. Bacterial genome size: 3 million letters - Kelly compares bacterial genomes to human genomes to illustrate complexity. Ginkgo facility size: 200,000 square feet - Kelly describes Ginkgo’s automated facility as a giant compiler/debugger for genetic code. Motif Foodworks raise: $226 million - Kelly cites Motif as an example of a company built on Ginkgo’s platform that raised significant capital. Motif team size: 35 people - Used to illustrate how a biology startup can scale without building its own lab infrastructure. SPAC PIPE: $775 million - Kelly says Ginkgo completed a large PIPE financing as part of going public. SPAC trust capital: $1.75 billion - Kelly mentions the SPAC structure brought substantial capital to scale Ginkgo. Bayer joint venture: $100 million - Kelly notes a joint venture with Bayer Crop Science focused on engineering microbes for fertilizer. Potential screening cadence for update follow-up: Month 4 phone call - Host describes an internal process where missing updates for several months trigger emails, Slack messages, and eventually a phone call. Proportion of startups that fail: 80% - Host cites this as the reason investors tend to treat missing updates as a serious warning sign.
Pivotal Quotes: "if your startup isn't sending you monthly investor updates, it's going out of business" — Jason Calacanis: Founder-university segment arguing that lack of investor communication is a major red flag. "biology is basically the AWS, the cloud computing platform for synthetic biology" — Jason Calacanis: Opening framing of Ginkgo BioWorks’ business model as infrastructure for programmable biology. "we suddenly have common language around the world to talk about this" — Jason Kelly: Kelly on COVID-19/mRNA making biotechnology and biological programming more legible to the public.
Implications: Founders should treat investor updates as an operating system, not a courtesy. In biotech, the biggest opportunity is industrial-scale biology, but the field will only grow safely if biosecurity, transparency, and trust advance as fast as the science.
About This Week in Startups
Jason Calacanis covers startups, tech, markets, media, and all the hottest topics in business and technology. He also interviews the world’s greatest founders, operators, investors, and innovators.